002007 Hualan Biological Engineering, Inc.
- 16.94
- -0.25-1.45%
Hualan Biological Engineering, Inc. News
Hualan Biology (002007): Blood products are growing steadily, and influenza vaccines are expected to be exchanged for price and quantity
Hualan Biology (002007): Rapid increase in pulp collection volume, new pulp station launched
Hualan Biology (002007): 1H24 blood products are growing steadily, and Chongqing was approved to establish a new pulp station
Hualan Biotech (002007): The company announced plans to increase its holdings and the blood products business is developing steadily
Hualan Biotech (002007): Actual controllers and executives plan to increase their holdings in the company to highlight long-term development potential
Hualan Biology (002007): Blood products business is steady awaiting the release of influenza vaccine
Hualan Biology (002007): The Q1 blood products business remains steady and we expect the influenza vaccine to be released
Hualan Biotech (002007): 1Q24 revenue was affected by seasonal fluctuations in vaccine, and the growth of blood products was relatively stable
Hualan Biology (002007): Stable blood products and vaccines return to normal
China Post Securities released a research report on April 26 stating that Hualan Biotech (002007.SZ) was given a purchase rating. The main reasons for the rating include: 1) The growth rate of blood products slowed down during the same period last year; 2
Hualan Biology (002007): The growth rate of pulp collection is impressive, and the blood products business is expected to accelerate
Hualan Biology (002007): Continued increase in the company's pulp collection is expected to drive the accelerated growth of the blood products business
Hualan Biotech (002007): Performance is in line with expectations, accelerated pulp collection lays the foundation for future growth
Hualan Biotech (002007): Performance is in line with expectations, slurry volume growth exceeds expectations
Hualan Biology (002007) Company Brief Review Report: Increased pulp collection volume can be expected to increase significantly
Hualan Biotech (002007): Blood products+vaccine dual-wheel drive will positively return shareholders in the next three years
Hualan Biotech (002007): Profitability of blood products enhances vaccine contribution performance flexibility
Hualan Biology (002007) 2023 Annual Report Review: Increased pulp collection and gradual increase in the competitiveness of vaccine companies
Hualan Biotech (002007): Profits slightly exceeded expectations, blood product plasma collection expanded rapidly
Hualan Biology (002007): Rapid increase in pulp collection and recovery of high vaccine growth
Analysis
Price Target
No Data
No Data